Reassuring news for postmenopausal women undergoing treatment for early breast cancer – Danish Cancer Institute
Danish Cancer Institute posted on LinkedIn about recent paper by Marie Lund et al., titled “Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data” published on The Lancet Oncology.
Authors: Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye
“NEWS: A new Danish study has provided reassuring news for postmenopausal women undergoing treatment for early breast cancer.
Published in The Lancet Oncology, the study found that women treated with aromatase inhibitors – a common hormone therapy used to prevent breast cancer recurrence – did not face an increased risk of major adverse cardiovascular events, defined as heart attack or ischemic stroke, compared to those who did not receive the treatment.
Clinical Associate Professor Marie Lund who led the study, says:
‘This is very good news for women undergoing this treatment. Our findings give reassurance that treatment with aromatase inhibitors does not pose a clinically relevant increased risk of ischemic cardiotoxicity.’
Mads Melbye, Head of Research at the Danish Cancer Institute and coauthor on the study:
‘These findings are important and reassures both patients and clinical staff that aromatase inhibitors can be used without compromising the patients heart health.’
Link to the findings in full below.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023